Copy Link Print Information

Ceralasertib

(Synonyms: AZD6738)
67 Cited Publications
Customer Review

Based on 67 publication(s) in Google Scholar

Ceralasertib (AZD6738) is an orally active and bioavailable inhibitor of ATR kinase with an IC50 of 1 nM.

For research use only. We do not sell to patients.

  • Purity: 99.43%
  • CAS No.: 1352226-88-0
  • Formula: C20H24N6O2S
  • Molecular Weight:412.51
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 1 year , -20°C, 6 months
  • Ceralasertib Chemical Structure
  • Experimental Validation Results for Ceralasertib
  • Experimental Validation Results for Ceralasertib
  • Experimental Validation Results for Ceralasertib
  • Experimental Validation Results for Ceralasertib
  • Experimental Validation Results for Ceralasertib
  • Ceralasertib Chemical Structure
    Ceralasertib Chemical Structure
  • Experimental Validation Results for Ceralasertib
  • Experimental Validation Results for Ceralasertib
  • Experimental Validation Results for Ceralasertib
  • Experimental Validation Results for Ceralasertib
  • Experimental Validation Results for Ceralasertib
CAS No.: 1352226-88-0
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Ceralasertib:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocol
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Ceralasertib

More
Customer Validation & Images
WBIn Vivo Efficacy StudyIF
  • WB
  • IF
  • WB
  • In Vivo Efficacy Study
  • WB

All ATM/ATR Isoforms

More
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Ceralasertib Chemical Structure
    Ceralasertib Chemical Structure
    1/16
  • 1/16

    Ceralasertib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Feb 16;15(1):1446. [Abstract]

    Customer Validation
     Immunoblot of KPC cells harboring doxycycline-inducible shRNA targeting luciferase, components of the PAF1c and MYC. Depletion was induced by doxycycline addition for 72 h and AZD6738 treatment for 72 h at 0.2 µM concentration. * refers to a non-specific band. Beta-actin was loading control (n=3).

  • 1/16

    Ceralasertib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Feb 16;15(1):1446. [Abstract]

    Customer Validation
     pKAP1(S824) intensity upon incubation with AZD6738 (0.1 µM; 24 h) (number of KPC cells plotted: siNTC: n=1654; siCDC73:n=1175).Scale bar: 10 µm. siRNA transfection was 48 h and EdU was added 30 minutes before fixation.

  • 1/16

    Ceralasertib purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2024 Jan 11;52(1):204-222. [Abstract]

    Customer Validation
     AZD6738 (1 μM) were administered for 30 minutes prior to UV irradiation (20 J/m2). HeLa cells were allowed to recover for 2 h after UV treatment, and phosphorylation of DHX9, Chk1, Chk2, and RPA32 was assessed by Western blot with indicated antibodies.

  • 1/16

    Ceralasertib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Aug 4;13(1):4520. [Abstract]

    Customer Validation
     ATR inhibitor AZD6738 prevent NCI‐H929 TP53−/− cell growth in NSG mice. NSG mice were subcutaneously injected with 106 NCI‐H929 TP53−/− cells (left panel). After 1 week, mice with detectable tumors were randomly distributed into four groups of seven mice and treated with AZD6738 (25 mg/kg; i.g., 5 times a week for 2 weeks), as indicated by the arrows (middle panel). The graphs represent the tumor volume kinetics (mean±SD, middle panel) and the tumor volume on Day 12 (right panel).

  • 1/16

    Ceralasertib purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2022 Nov 16;41(1):323. [Abstract]

    Customer Validation
     Ceralasertib (AZD6738; 1, 2 µM) signifcantly decreases the protein levels of ATR, IFI16 and HuR in a dose-dependent manner in GSC 267 and GSC 20 cells.

  • Ceralasertib